Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

GlaxoSmithKline Withdraws Application Seeking Patent for Antiretroviral Drug Combivir in India

August 23, 2006

GlaxoSmithKline withdrew a patent application in India for its twice-daily antiretroviral Combivir, Bloomberg/Philadelphia Inquirer reports. Although GSK did not give details as to why the application was withdrawn, N.Y. Sanglikar, spokesperson for the company's India unit, said in a telephone interview that it was withdrawn "voluntarily." Medecins Sans Frontieres in March said that groups in the country opposed the application because the drug was not new. The drug also would become more expensive because pharmaceutical companies that produce generic versions would have had to pay a "reasonable royalty" to the company, according to MSF (Bloomberg/Philadelphia Inquirer, 8/22).

Back to other news for August 23, 2006


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2006 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News

Tools
 

Advertisement